{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04956601",
      "orgStudyIdInfo": {
        "id": "ECART001"
      },
      "organization": {
        "fullName": "Peking University Third Hospital",
        "class": "OTHER"
      },
      "briefTitle": "Adjuvant Radiotherapy in Patients With Early Endometrial Cancer",
      "officialTitle": "A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification"
    },
    "statusModule": {
      "statusVerifiedDate": "2021-07",
      "overallStatus": "NOT_YET_RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2021-07",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-08",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2029-08",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2021-07-02",
      "studyFirstSubmitQcDate": "2021-07-02",
      "studyFirstPostDateStruct": {
        "date": "2021-07-09",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2021-07-02",
      "lastUpdatePostDateStruct": {
        "date": "2021-07-09",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Junjie Wang",
        "investigatorTitle": "Peking University Third Hospital",
        "investigatorAffiliation": "Peking University Third Hospital"
      },
      "leadSponsor": {
        "name": "Peking University Third Hospital",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.",
      "detailedDescription": "After being informed the study and potential risk，all patients giving written informed consent will be undergo a 1-week screening period determine eligibility for study entry. At week 0, patients who meet the eligibility will be randomized in a 1:1 ratio to vaginal brachytherapy or pelvic external beam radiotherapy. After treatment, patients were followed up regularly."
    },
    "conditionsModule": {
      "conditions": [
        "Endometrial Cancer",
        "Pathology",
        "Radiotherapy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 480,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "VBT",
          "type": "EXPERIMENTAL",
          "description": "CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w.",
          "interventionNames": [
            "Radiation: vaginal brachytherapy/pelvic external beam radiotherapy"
          ]
        },
        {
          "label": "EBRT",
          "type": "ACTIVE_COMPARATOR",
          "description": "Pelvic external beam radiotherapy，IMRT/VAMT，IGRT suggested，DT 45Gy/25f.",
          "interventionNames": [
            "Radiation: vaginal brachytherapy/pelvic external beam radiotherapy"
          ]
        }
      ],
      "interventions": [
        {
          "type": "RADIATION",
          "name": "vaginal brachytherapy/pelvic external beam radiotherapy",
          "description": "high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy",
          "armGroupLabels": [
            "EBRT",
            "VBT"
          ],
          "otherNames": [
            "Pelvic external beam radiotherapy"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "DFS",
          "description": "disease-free survival from being received treatment",
          "timeFrame": "5-year"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Failure mode",
          "description": "vaginal recurrences; pelvic recurrence; distant metastases",
          "timeFrame": "5-year"
        },
        {
          "measure": "OS",
          "description": "Overall survival from being received treatment",
          "timeFrame": "5-year"
        },
        {
          "measure": "Toxicities",
          "description": "from being received treatment",
          "timeFrame": "5-year"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;\n2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;\n3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;\n4. ECOG score is 0-2;\n5. The interval time between surgery and radiotherapy is no more than 8 weeks;\n6. The routine blood examination was normal;\n7. Compliance is good and informed consent is voluntarily signed.\n\nExclusion Criteria:\n\n1. The patients receive chemotherapy;\n2. History of previous malignant disease;\n3. Previous diagnosis of Crohn's disease or ulcerative colitis.",
      "healthyVolunteers": false,
      "sex": "FEMALE",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Junjie Wang",
          "role": "CONTACT",
          "phone": "861082265920",
          "email": "junjiewang_edu@sina.cn"
        }
      ],
      "locations": [
        {
          "facility": "Peking University 3rd Hospital",
          "city": "Beijing",
          "state": "Beijng",
          "zip": "100191",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "UNDECIDED"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D016889",
          "term": "Endometrial Neoplasms"
        }
      ],
      "ancestors": [
        {
          "id": "D014594",
          "term": "Uterine Neoplasms"
        },
        {
          "id": "D005833",
          "term": "Genital Neoplasms, Female"
        },
        {
          "id": "D014565",
          "term": "Urogenital Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D014591",
          "term": "Uterine Diseases"
        },
        {
          "id": "D005831",
          "term": "Genital Diseases, Female"
        },
        {
          "id": "D052776",
          "term": "Female Urogenital Diseases"
        },
        {
          "id": "D005261",
          "term": "Female Urogenital Diseases and Pregnancy Complications"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D000091662",
          "term": "Genital Diseases"
        }
      ]
    }
  },
  "hasResults": false
}